Turning Point Therapeutics Inc. (TPTX) PT Raised to $155 at Wedbush, Following Earnings
- Wall Street falls as Amazon earnings disappoint
- Amazon (AMZN) Plunges After Missing Sales and Guidance Expectations, Analysts Slash PTs to Reflect Weaker Guidance
- Pinterest (PINS) Tops Profit and Sales Views, But Shares Plunges Over 20% on a Big Monthly User Miss to Prompt Two Downgrades
- 'I'm CEO.' New Book Outlines Merger Conversations Between Elon Musk and Tim Cook
- Bullard: Fed should taper this fall, go "fairly rapidly" to end early 2022
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten raised the price target on Turning Point Therapeutics Inc. (NASDAQ: TPTX) to $155.00 (from $136.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerner (CERN) PT Raised to $87 at Cantor Fitzgerald Following Earnings
- M.D.C. Holdings (MDC) PT Raised to $63 at Wedbush, Following Earnings
- Banco de Sabadell SA (SAB:SM) (BNDSF) PT Raised to EUR0.62 at Deutsche Bank
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!